$CGEM News

Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42

Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones

Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate

BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39

Cullinan Therapeutics Announces Positive Feedback From FDA Following End-Of-Phase 1 Meeting For CLN-049, FLT3xCD3 T Cell Engager Being Evaluated In Patients With Acute Myeloid Leukemia

Cullinan Therapeutics: Heading Toward Paydirt

Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases - Slideshow

Cullinan Therapeutics Reports Clinical Data And Outlines Global Clinical Development Plans For CLN-978, CD19xCD3 T Cell Engager, And Velinotamig, BCMAxCD3 T Cell Engager

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE And RA Patients Following Single Target Dose In Phase 1 Trial

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutional Investors On June 10

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

The FDA Grants Orphan Drug Designation To Cullinan Therapeutics' CLN-049 For Relapsed/Refractory Acute Myeloid Leukemia

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress